Viaderma Inc (OTCMKTS:VDRM) is a penny stock that has started to engage some focus among traders and investors as prices get a little traction in bounce mode. The company caught a bit of renewed momentum last week as a consequence of its announcement of a first order from its product manufacturer for a rollout of its FDA-registered drug, Viabecline, a topical antibiotic.
According to the release, the Company expects sales for 2017 to be about 500,000 units and has completed financing to produce the orders. “The rollout in California is expected to start with approximately 10,000 units being distributed online through an online network of affiliates. The products are anticipated to sell for approximately $125 per 5ml bottle, with a wholesale price to be established for the Clinics & Wound Care Centers.”
Viaderma Inc (OTCMKTS:VDRM) bills itself as a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas.
ViaDerma’s lead product, TetraStem, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets.
The company is moving aggressively into the medicinal marijuana space.
According to company materials, “ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, Patent application using the combination of CBD’s and THC with the delivery system was filed in 2014. The use of CBD’s is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.”
Find out when $VDRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Management expressed obvious confidence in the strong outcome.
“I believe these orders will give us a significant increase in revenues for 2017. ViaDerma has had clinical success in a very short time frame,” said CEO Dr. Christopher Otiko. “We are excited to see our research being so well received in so many countries. This opens the door for many new products using FDA approved drugs along with our ‘proprietary transdermal delivery system.'”
“ViaDerma has also completed an initial clinical study of our proprietary medication for onychomycosis (toenail fungus), and the results were very encouraging with an approximate 80% success rate,” said Dr. Otiko.
According to the company, Onychomycosis affects approximately 5% of the worldwide population. One of the more popular medications on the market has a 17% success rate and can cost as much as $500 per 4ml bottle. Americans currently spend about $1.26 billion annually on oral and topical prescriptions for nail fungus, according to IMS Health, a healthcare information company. Industry analysts and executives estimate that more effective treatments could expand the market to as much as $3 billion annually.
We’ve witnessed a bit more than 710% tacked on to share pricing for the name in the past month. This is emblematic of the stock. VDRM has a track record that includes a number of dramatic bounces. Furthermore, the stock has benefitted from a jump in recent trading volume to the tune of topping 280% beyond its prior sustained average level.
Currently trading at a market capitalization of $3.4M, VDRM has virtually no cash on the books, which compares with about $217K in total current liabilities. VDRM is pulling in trailing 12-month revenues of $306K. In addition, the company is seeing major top line growth, with y/y quarterly revenues growing at 8.8%. You can bet we will update this one again as new information comes into view. For continuing coverage on shares of $VDRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!
